The FDA first approved nitisinone in 2002 for managing and treating hereditary tyrosinemia type 1 (HT-1). HT-1 is an autosomal recessive disease caused by a deficiency in fumarylacetoacetate hydrolase (FAH), the last enzyme in the tyrosine degradation pathway. This activity reviews the indications, action, and contraindications for nitisinone as a valuable agent in treating HT-1 and its off-label use in managing alkaptonuria. This activity highlights the mechanism of action, adverse event profile, and other key factors (e.g., dosing, pharmacodynamics, monitoring) of nitisinone therapy, pertinent for members of the interprofessional healthcare team in managing hereditary tyrosinemia type 1 and related metabolic disorders.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/150084
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, All Practice Areas (e.g. ethics), Developmental-Behavioral Pediatrics, General Pediatrics, General Surgery, Hospital Medicine, Internal Medicine, Neonatal-Perinatal Medicine, Neurodevelopmental Disabilities, Pediatric Endocrinology, Pediatric Gastroenterology, Pediatric Nephrology, Pediatric Neurology, Pediatric Transplant Hepatology
Subscribe
Login
0 Comments
Oldest